Vemurafenib, which will be available as Zelboraf, is now recommended for treating patients with metastatic BRAF V600 mutation-positive melanoma, which affects nearly half of all melanoma patients while Bristol-Myers Squibb's ipilimumab vaccine, to be sold under the brand name Yervoy, will be used to treat patients with advanced malignant melanoma who have received prior chemotherapy.
"These new draft recommendations represent really good news for skin cancer patients. Vemurafenib and ipilimumab are breakthrough treatments that can potentially significantly affect prognosis for these patients and we are very pleased that the manufacturers have worked with us so that we are now able to recommend both ipilimumab and vemurafenib", Nice's Professor Carole Longson said.
Source: Medindia